

Civica Expands Product Offerings to Include Sodium Phosphates Injection, USP

Lehi, UT — September 24, 2025 Civica, a nonprofit pharmaceutical company created to prevent and mitigate drug shortages, is proud to announce the launch of Sodium Phosphates Injection, USP. This comes at a critical time for U.S. hospitals and patients, who often feel the impacts of shortages of essential generic medicines.

"For years, Sodium Phosphates Injections have faced intermittent shortages in the United States. Drug shortages can be caused by multiple factors, such as manufacturing delays, raw material supply challenges, and limited suppliers," said Ned McCoy, President and CEO of Civica.

Total parenteral nutrition (TPN) is complete nutrition delivered intravenously to people who can't use their digestive systems at all. TPN might be required when certain conditions impair a patient's ability to process food and absorb nutrients through their digestive tract, or when they need to avoid using their digestive system for a while so it can heal. It is estimated that about 34,000 patients rely on parenteral nutrition each year.

Sodium Phosphates Injection, USP is indicated as a source of phosphorus, for addition to intravenous fluids, to prevent or correct hypophosphatemia (dangerously low phosphate levels in the blood) in patients with restricted or no oral intake. It is also useful as an additive to other parenteral fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions.

Hospital pharmacists and physicians help prioritize the medications Civica provides. The company's current product offerings include generic sterile injectables, many of which are used in urgent care settings. Due to their low cost, generic medications are particularly susceptible to shortage. Shortages of these essential medications can delay medical care and negatively impact patient outcomes.

"Civica's entry into the market provides hospitals with added reliability and resilience in the supply chain," added McCoy.

The Civica Sodium Phosphates Injection, USP medicine will be available to order through the Cencora Online Ordering Platform.

About Civica

Founded in 2018 by innovative healthcare leaders nationwide, Civica is a pharmaceutical nonprofit dedicated to ensuring the accessibility, affordability and quality of essential generic injectables and biosimilar insulins. With 60 members, including leading health systems, hospitals, and philanthropic organizations, Civica supplies more than 70 essential medicines to over 1,400 hospitals, supporting care for over 90 million patients. By committing to long-term

contracts and targeting six months of safety stock, we help stabilize the market and reduce the impact of shortages.

About Sodium Phosphates Injection

For full prescribing information and patient information, including warnings and precautions, potential adverse reactions and drug interactions, please refer to the Package Insert, available [here](#). You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [MedWatch: The FDA Safety Information and Adverse Event Reporting Program | FDA](#) or call 1-800-FDA-1088.

To learn more about Civica or become a member, please contact: Michael.Laffin@civicarx.org

For media inquiries, please contact: Liz.Power@civicarx.org

###